Myeloid

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting.

Leave a Comment / Novel / By

Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting. Read More »

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

Leave a Comment / Novel / By

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting Read More »